鲁索替尼治疗伴有PCM1-JAK2融合基因的B淋巴细胞白血病的疗效 - Suppr | 超能文献

相似文献

1

Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.鲁索替尼治疗伴有PCM1-JAK2融合基因的B淋巴细胞白血病的疗效

Br J Haematol. 2021 Feb;192(4):e112-e115. doi: 10.1111/bjh.17340. Epub 2021 Jan 27.

2

Larotrectinib in TRK fusion-positive pediatric B-cell acute lymphoblastic leukemia.拉罗替尼治疗 TRK 融合阳性小儿 B 细胞急性淋巴细胞白血病。

Blood Adv. 2019 Nov 26;3(22):3499-3502. doi: 10.1182/bloodadvances.2019000700.

3

Sustained remission after ruxolitinib and chimeric antigen receptor T-cell therapy bridged to a second allogeneic hematopoietic stem cell transplantation for relapsed Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with novel NPHP3-JAK2 fusion.鲁索替尼和嵌合抗原受体T细胞疗法后持续缓解，桥接至第二次异基因造血干细胞移植，用于治疗复发的具有新型NPHP3-JAK2融合的费城染色体样B细胞前体急性淋巴细胞白血病。

Genes Chromosomes Cancer. 2022 Jan;61(1):55-58. doi: 10.1002/gcc.22995. Epub 2021 Sep 1.

4

The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and gene fusion presenting as B-lymphoblastic leukemia.表现为 B 淋巴母细胞白血病的伴嗜酸性粒细胞和基因融合的髓系/淋系肿瘤的诊断挑战和临床经过。

Cold Spring Harb Mol Case Stud. 2020 Apr 1;6(2). doi: 10.1101/mcs.a004937. Print 2020 Apr.

5

New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia.B细胞前体急性淋巴细胞白血病中新出现的预后和预测性遗传生物标志物

Haematologica. 2016 Apr;101(4):407-16. doi: 10.3324/haematol.2015.141101.

6

Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.芦可替尼在伴有PCM1-JAK2融合基因的髓系肿瘤中的疗效。

Ann Hematol. 2015 Nov;94(11):1927-8. doi: 10.1007/s00277-015-2451-7. Epub 2015 Jul 23.

7

Identification of a novel GOLGA4-JAK2 fusion gene in B-cell acute lymphoblastic leukaemia.在 B 细胞急性淋巴细胞白血病中鉴定到一个新型 GOLGA4-JAK2 融合基因。

Br J Haematol. 2022 Feb;196(3):700-705. doi: 10.1111/bjh.17910. Epub 2021 Oct 25.

8

TLE3 Is a Novel Fusion Partner of JAK2 in Myeloid/Lymphoid Neoplasm With Eosinophilia Responding to JAK2 Inhibition.TLE3 是一种新型融合伙伴，存在于伴有嗜酸性粒细胞增多的髓系/淋巴系肿瘤中，对 JAK2 抑制有反应。

Genes Chromosomes Cancer. 2024 Aug;63(8):e23261. doi: 10.1002/gcc.23261.

9

Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia.芦可替尼纳入针对B前体急性淋巴细胞白血病中一种新型JAK2 F694L突变的剂量强化疗法。

Pediatr Blood Cancer. 2017 May;64(5). doi: 10.1002/pbc.26328. Epub 2016 Nov 15.

10

Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.鲁索替尼治疗伴有PCM1-JAK2和BCR-JAK2融合基因的髓系肿瘤时完全缓解的持续时间有限。

Ann Hematol. 2015 Feb;94(2):233-8. doi: 10.1007/s00277-014-2221-y. Epub 2014 Sep 27.

引用本文的文献

1

The Use of Optical Genome Mapping for the Detection of Tyrosine Kinase Gene Fusions in Myeloid/Lymphoid Neoplasms.光学基因组图谱在检测髓系/淋巴系肿瘤中酪氨酸激酶基因融合方面的应用

J Cell Mol Med. 2025 Jun;29(12):e70640. doi: 10.1111/jcmm.70640.

2

NKD1 targeting PCM1 regulates the therapeutic effects of homoharringtonine on colorectal cancer.靶向 NKD1 的 PCM1 调控高三尖杉酯碱治疗结直肠癌的疗效。

Mol Biol Rep. 2023 Aug;50(8):6543-6556. doi: 10.1007/s11033-023-08572-5. Epub 2023 Jun 20.

3

PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature.